A CD52 antibody impairs mouse-transplanted intestinal tight junctions

Area of Science:

• Immunology
• Gastroenterology
• Transplantation Science

Background:

• CD52 monoclonal antibody (mAb) use in small bowel transplantation improves outcomes.
• The impact of CD52 mAb on intestinal barrier microstructure, specifically tight junctions (TJs), remains understudied.
• Bacterial translocation is a critical concern in transplantation, highlighting the importance of intestinal barrier integrity.

Purpose of the Study:

• To investigate the effect of a CD52 mAb on the ultrastructure and function of tight junctions (TJs) in transplanted intestines.
• To assess the impact of CD52 mAb on TJ protein expression and distribution.
• To evaluate changes in intestinal permeability following CD52 mAb administration in a murine model.

Main Methods:

• Utilized a murine orthotopic small bowel transplantation model.
• Examined TJ ultrastructure using transmission electron microscopy.
• Quantified TJ protein expression (occludin, ZO-1) via Western blot and immunofluorescence.
• Assessed in vivo intestinal permeability using FITC-dextran.

Main Results:

• CD52 mAb application resulted in compromised TJ ultrastructure.
• Expression of TJ proteins occludin and ZO-1 was significantly decreased.
• Intestinal permeability was found to be increased post-CD52 mAb treatment.

Conclusions:

• The anti-mouse CD52 mAb negatively impacts the integrity of tight junctions in transplanted intestines.
• CD52 mAb treatment impairs the intestinal barrier function, potentially increasing the risk of bacterial translocation.
• Further research is warranted to understand the long-term implications and potential mitigation strategies.